10-Q/A - BioNexus Gene Lab Corp (0001737523) (Filer)

Fri, May 31, 8:01 PM (56 days ago)

BioNexus Gene Lab Corp. filed Amendment No. 2 to its Form 10-Q for the quarter ended September 30, 2023, in response to a Comment Letter from the SEC. This amendment specifically revises Part 1, Item 4 on Controls and Procedures, correcting the terminology to comply with Item 307 of Regulation S-K. The original filing incorrectly stated that the controls and procedures were "capable," which did not meet the regulatory requirements. The amendment clarifies that the company's disclosure controls and procedures were not effective as of the end of the reporting period. No changes were made to the financial statements or other sections of the original filing. There were no material changes in internal controls over financial reporting during the period. This amendment should be read in conjunction with the original filings and other SEC submissions by the company.